|
OmniComm expands global reach with new deals
July 2017
EDIT CONNECT
SHARING OPTIONS:
OmniComm Systems, a leading strategic software solutions provider, has been selected to provide electronic data capture (EDC) software
and services to a major contract research organization (CRO) with locations in the United States and Europe. The deal is the latest contract in a string of
recent international partnerships. Under the terms of the most recent deal, the CRO will utilize OmniComm’s TrialOne system to standardize clinical
development programs, ensure regulatory compliance and bring greater operational efficiency, speed and quality to the clinical research process within its
clinics.
OmniComm provides comprehensive solutions for clinical research with experience from over 5,000 clinical
trials. Through the use of innovative and progressive technologies, OmniComm says it helps the life-sciences industry to drive efficiency in clinical
development, better manage risks, ensure regulatory compliance and manage clinical operations performance. Its TrialOne system is a browser-based data
collection technology specifically designed to automate the workflows and processes within early-phase research clinics.
The CRO will use TrialOne to implement a number of automated clinical trial processes across multiple clinics, including the
recruitment and screening of subject participants, study design work and the collection, analysis and reporting of data. Future project initiatives will
include multiple interfaces with clinic equipment such as blood pressure sensors and electrocardiogram devices. The CRO reportedly chose TrialOne because of
its ability to manage and optimize patient screening and recruitment, implement data capture from subject at the bedside, automate data capture from medical
monitoring equipment and devices, streamline staff training and support records and integrate with laboratory information management systems for lab orders
and lab results processing.
“With this project award, TrialOne’s position as the market-leading
eSource solution for Phase 1 clinics is now solidified,” said Kuno van der Post, OmniComm’s chief commercial officer. “We are absolutely
thrilled to have been selected, more so as it comes after a period of significant investment within OmniComm in both product quality and highly skilled
support resources. The timing could not have been better.”
OmniComm also recently signed its fourth and
fifth contracts to implement TrialOne in China, all since it made its debut there in December 2016. Regulatory changes in China have increased the importance
and necessity of clinic automation systems during clinical trials. Currently, early-phase research centers lack the systems needed to manage clinical
trials, while addressing the regulatory requirements for data quality and integrity.
TrialOne was selected for
several reasons, including its ability to support the Chinese language. As a system that is compliant with global industry standards and best practices for
Phase 1 clinical research, TrialOne helps user organizations to ensure the quality and integrity of the data collected and managed during the clinical trial
process. TrialOne’s ability to enable users to comply with Chinese FDA regulations aimed at harmonizing local practices to global standards was also a
key factor influencing its adoption.
“TrialOne is rapidly being recognized as a solution that can help Phase
1 clinics and early-phase research organizations in China to standardize their processes, manage compliance with regulatory requirements and international
standards, secure data integrity and data quality, while at the same time increasing the efficiency of their operations,” said Wolf Ondracek, managing
director and senior vice president at OmniComm. “These two new customers—one located in Guangzhou—add to the geographical spread of
TrialOne implementations in China, and this strengthens our confidence in the potential for impressive TrialOne growth during the course of the
year.”
Over the last year, OmniComm’s reach has broadened across the globe. In addition to being
chosen by a number of top hospitals and research universities around Europe and the United States, the company’s expansion into China is complemented
by major contracts in Canada, Israel and Australia. One of its signature products, TrialMaster, supports any number of languages, meaning a trial can be
designed and built and the metadata translated into the desired languages so that users can pick the language of their choice. According to their website,
the clinical data itself is effectively language-agnostic, since numbers and dates are universal while coded fields contain an internal value rather than a
language-dependent label. Only free text fields may need manual translation. This means, for example, that a trial may be conducted in English, Spanish,
French and Japanese, but be analyzed in English.
Code: E071718 Back |
Home |
FAQs |
Search |
Submit News Release |
Site Map |
About Us |
Advertising |
Resources |
Contact Us |
Terms & Conditions |
Privacy Policy
|